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Abstract 
Over the last decade, there has been an increasing scientific and public interest in bacteria that may 
positively contribute to human gut health and well-being. This interest is reflected by the ever-increasing 
number of developed functional food products containing health-promoting bacteria and reaching the 
market place as well as by the growing revenue and profits of notably bacterial supplements worldwide. 
Traditionally, the origin of probiotic-marketed bacteria was limited to a rather small number of bacterial 
species that mostly belong to lactic acid bacteria and bifidobacteria. Intensifying research efforts on the 
human gut microbiome offered novel insights into the role of human gut microbiota in health and disease, 
while also providing a deep and increasingly comprehensive understanding of the bacterial communities 
present in this complex ecosystem and their interactions with the gut-liver-brain axis. This resulted in 
rational and systematic approaches to select novel health-promoting bacteria or to engineer existing 
bacteria with enhanced probiotic properties. In parallel, the field of gut microbiomics developed into a 
fertile framework for the identification, isolation and characterization of a phylogenetically diverse array of 
health-promoting bacterial species, also called next-generation therapeutic bacteria. The present review 
will address these developments with specific attention for the selection and improvement of a selected 
number of health-promoting bacterial species and strains that are extensively studied or hold promise for 
future food or pharma product development. 
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Abbreviations 
CRISPR clustered regularly interspaced short palindromic repeats 
GI gastro-intestinal tract 
GMO genetically modified organism 
LAB lactic acid bacteria 
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1. Introduction 
The complexity of the human microbiota as well as its important implications for human health have been 
subject to a rapidly growing interest. A plethora of studies showed associations between the gut microbiota 
composition and infections, diseases or clinical conditions, paving the way to novel diagnostic approaches 
based on specific bacterial signatures found in patients (Flemer et al., 2018; Gilbert et al., 2016; Kahrstrom 
et al., 2016). Bacteria persisting in the human gut were found to interact with the host cells and other 
inhabitants of the gut as well as to play an immunomodulatory role (Hemarajata and Versalovic, 2013; 
Thaiss et al., 2016) and have systemic effects, among others via the gut-liver-brain axis (Collins et al., 2012; 
Sherwin et al., 2016). Moreover, it has been found that diet is one of the most important drivers of the 
microbiota composition and activity that in turn have an important systemic impact (Salonen and de Vos, 
2014; Sonnenburg and Backhed, 2016). Of relevance for the food industry, the gut microbiota composition 
was shown to determine the impact of dietary interventions (Cotillard et al., 2013; Salonen and de Vos, 
2014). Similarly, various studies have highlighted the contribution of the gut microbiota on the way 
individuals respond to specific drug therapies, bringing the interest in the intestinal microbiome in the 
realm of the pharma industry (Routy et al., 2018). 
The biotechnology of functional food products has mainly focused on probiotics, defined as “live 
microorganisms that, when administered in adequate amounts, confer a health benefit on the host” (Hill et 
al., 2014). Typical traditional probiotics include lactic acid bacteria (LAB) and bifidobacteria (Figure 1) that 
are known to have a long history of safe use and are therefore well established on the probiotic market. 
The strong growth of the probiotic market has justified the need for further product development and 
diversification but also for the design and elaboration of the next-generation of live therapeutics and 
functional food products. Three main developments can be distinguished. The first includes intensified 
efforts to identify, characterize and select new probiotic candidates belonging to LAB and bifidobacteria 
with regard to their respective health-promoting properties to humans. In addition to the human body, i.e. 
gastro-intestinal tract (Goldin et al., 1992) or oral cavity (Beighton et al., 2008), a wider array of isolation 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
sources have been explored and screened for probiotic candidates (Sornplang and Piyadeatsoontorn, 
2016). Recent work on human gut health also resulted to a more rational and systematic approach based 
on genomics and other omics approaches, in vitro and in vivo assays to investigate the potential functional 
properties of these health-promoting bacteria (Figure 2). The second development relates to the use of 
genetic engineering tools since they offer novel strategies to enhance properties of health-promoting 
bacteria (Mays and Nair, 2018). While regulatory and safety aspects will not be addressed here, it is 
important to distinguish approaches that do not generate genetically modified organisms (GMOs), which 
are regulated strictly in Europe, versus the non-GMO approaches that lead to industrial strains that can be 
used without further specific limitations (Directive 2001/18/EC). The latter include bacterial strains 
improved by classical mutations or natural gene transfer systems (Bron et al., 2018). However, a different 
position is associated with the revolutionary CRISPR-Cas based genome-editing technology (Mougiakos et 
al., 2016). Presently, the regulations for the CRISPR-Cas technology are not uniformly adopted in all parts of 
the world and time will tell what the impact will be on bacterial engineering (Callaway, 2018). The final 
development involves the identification of novel gut bacteria not belonging to the traditional lactobacilli-
bifidobacteria groups that emerged from the detailed characterization of the gut microbial composition (El 
Hage et al., 2017; O'Toole et al., 2017). These so-called next-generation therapeutic bacteria, including 
among others Faecalibacterium prausnitzii or Akkermansia muciniphila, display traits that are distinct from 
the ones reported in traditional probiotics (Cani and de Vos, 2017; Martin et al., 2018). Moreover, as these 
bacteria are natural gut commensals, it has been suggested that their use may result in longer colonization 
than traditional probiotic strains that do not colonize the human gut, where their effects persist only during 
a short period of time (Schmidt, 2013). Whether this is true remains to be seen since recent deep 
metagenomic sequencing studies of fecal microbiota transplants showed that there is considerable 
competition between strains of the same commensal species in the human gut (Li et al 2016).  
 The present review will discuss the increasing importance of the market of health-promoting bacteria and 
address the recent research developments of a selected number of bacterial species and strains that are 
widely commercialized worldwide and extensively researched. Finally, we will review novel health-
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promoting bacterial species that hold great potential for future developments of health-promoting 
functional products or therapeutics.  
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2. Market development and production of health-promoting bacteria 
The benefits of probiotic taxa have been well documented and their characterization at the molecular level 
is progressing (Sanders et al., 2018). However, only a limited number of approved claims have been 
associated with probiotic bacteria, possibly because of the way the health benefits are recorded and used 
in regulatory processes (Kleerebezem et al., 2018). In spite of these limitations, the market developments 
have shown a great interest by the consumer. Recent reports estimate the 2017 market for probiotic 
bacteria to be over 40 billion dollars and expect that to grow with an annual growth rate of approximately 
7%, depending on the region in the world, to over 65 billion dollars in 2022 (Global Market Insight, 2018; 
Occams Business, 2017). This includes probiotics in foods and beverages with specifically the dairy segment 
to grow while some differences between growth of different species of Lactobacillus, Bifidobacterium and 
Streptococcus spp. were noted with growth rates of 8.5 %, 6% and 7.5 %, respectively (Global Market 
Insight, 2018). It should be noted that these and other market data are based on soft data that were not 
peer reviewed and hence the absolute numbers may vary but the trends are likely very real and have been 
recently reviewed (Taroncher-Oldenburg et al., 2018). In 2017, the total investment was over 500 million 
dollar, mainly focusing on therapeutics and around 10 % on diagnostics. This parallels the global market 
expectations for human microbiome-based therapeutics and diagnostics that reportedly is expected to 
grow to close to 1 billion dollar in 2024 (Markets and Markets, 2017; McKellar et al., 2017; Roots Analysis 
Business Research & Consulting, 2017). This includes next-generation therapeutic bacteria as sole culture or 
combination as well as their products.  
Due to decades of experience, the cost-effective production of probiotics belonging to the canonical 
Lactobacilli, Bifidobacteria and Streptococci has been well established. However, as live bacteria are 
required in probiotic powder formulations, there has been considerable attention for preserving viability 
after freeze or spray-drying by enhancing stress resistance, optimizing protectants and improving the 
production process and dryer settings (Broeckx et al., 2016; Fu et al., 2018). Here, omics approaches such 
as proteomics are showing potential and together with flow-cytometry based techniques for assessing 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
single cell viability offer options for improvements (Chiron et al., 2018; Mangiapane et al., 2015). Similarly, 
post-drying processes are being optimized and various encapsulation techniques have been described and 
reviewed (Coghetto et al., 2016; Sipailiene and Petraityte, 2018). While most of the canonical probiotic 
bacteria can tolerate and even use some oxygen, most of the next-generation therapeutic bacteria are 
strict anaerobes. Hence, the encapsulation and viable delivery of these may be pivotal (Marcial-Coba et al., 
2018; van der Ark et al., 2017a).  
The availability of genomes of probiotic bacteria allowed the development of genome-scale models that 
could support production optimization. However, this omics-based growth optimization for traditional 
probiotic bacteria has received only limited attention, in spite of the successful application of such models 
(Teusink et al., 2006). This may be explained by the empirical optimization methods that have led to 
present day biotechnological applications of the canonical probiotic bacteria. However, this does not hold 
for next-generation therapeutic bacteria that often have just been isolated from the human gut and here 
model-driven optimization has shown to be very productive (van der Ark et al., 2017b). For the strict 
anaerobe Faecalibacterium prauznitzii, this resulted in an improved understanding of its growth 
requirements for butyrate production and its metabolic cross talk with Bifidobacterium adolescentis (El-
Semman et al., 2014). In the case of Akkermansia muciniphila, which was isolated as a mucus degrader, a 
genome-scale model led to the identification of growth parameters and the design of an animal-component 
free synthetic medium (van der Ark et al., 2018). This and other applications are expected to be 
instrumental in rapidly succeeding in producing these next-generation therapeutic bacteria to an industrial 
scale that is necessary for their application as health-promoting bacteria.  
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3. Selection of traditional health-promoting bacterial species: a long and ongoing story 
Historically and culturally, fermented foods have been associated with the human diet for a very long time, 
i.e. kimchi, kefir, yoghurt, sour milk or cheese (Shortt, 1999) and the development of food fermentation 
and preservation methods contributed to the domestication of some of these bacterial species (Douglas 
and Klaenhammer, 2010). Health-promoting properties of several of these microorganisms have been since 
well-documented but until recently, the detailed molecular mechanisms behind it and their roles on the gut 
microbiota were not well understood. Using classical and well-established screening methods, novel 
probiotic strains are now selected based on a number of well-defined criteria as established by FAO and 
WHO (Araya et al., 2002). These criteria relate to phenotypic/genotypic traits and functional properties, 
such as strain identification, stress tolerance, adherence to mucosa or intestinal epithelium, or safety (de 
Melo Pereira et al., 2018). Based on these recommendations, there is a growing number of novel strains or 
isolates from the canonical lactobacilli and bifidobacteria that have been classified as probiotics. In addition 
to generic criteria for selecting probiotics, functional properties of strains should be further studied for 
treating specific health conditions, i.e. cancer (Yamane et al., 2018), depression (Aizawa et al., 2016; Rudzki 
et al., 2018), obesity (Kim et al., 2018; Lee et al., 2018; Park et al., 2018) or diabetes (Khalili et al., 2018; Liu 
et al., 2018). Beside the probiotic properties of these strains, industrial considerations and production 
aspects are essential to allow the commercialization of these probiotics. Thus, traditional commercialized 
probiotics display phenotypic traits that are also compatible with industrials processes and that do not alter 
the organoleptic properties of the food products (Gueimonde and Sanchez, 2012). 
Since the whole sequencing of the bacterial genome of Haemophilus influenza (Fleischmann et al., 1995), 
there has been literally a revolution in the field of genome sequencing technologies. The development of 
next-generation whole genomic sequencing allowed in-depth characterization of the coding capacity of 
probiotic strains, unveiling genes associated with probiotic traits. Functional genomics brought insights into 
molecular mechanisms and mode of action of probiotic strains, resulting in the identification novel sets of 
genes associated with probiotic functions. Notable probiotic and/or widely commercialized strains were 
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among the first lactobacilli and bifidobacteria to be sequenced but were soon followed with the genome 
sequencing of a plethora of other isolates, as this is illustrated by the number of deposited genomes of 
traditional probiotics (Table 1). This provided insights into the phylogenetic diversity of LAB and 
bifidobacteria. For example, Lactobacillus rhamnosus, Lactobacillus salivarius or Lactobacillus sakei were 
found to have a high intra-species diversity (Ceapa et al., 2016; Chaillou et al., 2013; Douillard et al., 2013; 
Harris et al., 2017), underlying that functional properties towards the host are very much strain-dependent. 
Moreover, following the deep analysis of hundreds of Lactobacillus genomes, their taxonomy is being 
revised and this may lead to a new nomenclature for the presently 12 phylogroups that have been detected 
(Salvetti et al., 2018). In contrast, the diversity of species like Bifidobacterium animalis subsp. lactis is 
singularly low, indicating that the strains of this species share a recent ancestor (Milani et al., 2013) and 
therefore may display comparable phenotypic traits. Initial comparative genomic analysis at the species 
levels also provided important data on how to select new isolates in a given species by identifying sets of 
genes that are known to be associated with probiotic functions, such as adherence or stress tolerance. For 
example, in Lactobacillus rhamnosus, comparative genomic analysis of two strains (GG and Lc705) led to 
the identification of a gene cluster (spaCBA-srtC1) coding for sortase-dependent pili that adheres to the 
intestinal mucosa, which was then further confirmed by in vitro assays and animal models (Kankainen et al., 
2009). Similarly, in Bifidobacterium breve UCC2003, genes encoding type IVb tight adherence (Tad) fimbriae 
were uncovered (O'Connell Motherway et al., 2011). In Lactobacillus salivarius strain UCC118, genes coding 
for mucus-binding LPXTG proteins were identified and assessed by adhesion assays (van Pijkeren et al., 
2006). The number of genes associated with probiotic functions is constantly growing and brings novel 
insights into the mode of action of health-promoting bacteria in the gut (Lebeer et al., 2018; Lebeer et al., 
2008). Their availability constitutes important information for the selection of probiotic candidates. It 
includes dozens of genes associated with survival in the GI tract, host-bacteria interaction, 
immunomodulation, antimicrobial activity or pathogen control, for a recent review see (Lebeer et al., 
2018). In addition to selecting for probiotic traits, genome sequencing allows the identification of genes 
associated with virulence and antibiotic resistance (safety assessment) and an accurate taxonomic 
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identification of the strains (Figure 3), since in some cases, 16S rRNA gene sequencing is not suitable for 
species determination (Torriani et al., 2001). By screening and selecting in silico strains, larger pool of 
isolates can be analyzed prior to any wet lab analyses, preventing extensive and fastidious laboratory 
screening. Genomic sequencing of probiotic candidates do, however, have technical bottlenecks, since 
there is not always an evident association between gene and function, justifying need to conduct 
phenotypic characterization and complementary omics approaches, like transcriptomics, metabolomics, 
methylomics or proteomics to further comprehend gene activity under various culturing conditions and 
more broadly mode of actions of health-promoting bacteria, i.e. heat shock (Rezzonico et al., 2007), bile 
salt resistance (Ruiz et al., 2012), acid stress (Koponen et al., 2012) or anti-microbial compound production 
(Riboulet-Bisson et al., 2012). 
 
4. Tools and techniques for improvement of health-promoting bacteria 
Criteria for selecting probiotic bacteria isolated from various ecological niches are well established and in 
conjugation with omic approaches, this allows high-throughput and efficient mining of novel isolates with 
probiotic potential. However, existing probiotic strains were shown to have limited effects in some cases, 
as previously reported (Bomba et al., 2002; Karimi and Pena, 2008; Koo et al., 2012). The increasing 
knowledge on the mode of action of probiotic bacteria in the gut towards the host and its associated 
microbiota now offers a basis for the rationale design of bio-engineered probiotic strains with tailored 
functional properties. The improvement, alteration or acquisition of phenotypic traits in existing probiotic 
strains can positively impact their performance and function in the gut. Thus, bio-engineered traits may 
relate to colonization in the gut, i.e. mucosal adherence or acid stress resistance, immuno-modulation, 
antimicrobial activity or production/display of enzymes or structural proteins, metabolites or active 
compounds in the gut (Figure 4). Bio-engineering of probiotic strains also offers the possibility to delete 
problematic genes, i.e. antibiotic resistance and virulence genes that were initially reported in isolates with 
probiotic potential. The need for this may increase as various Lactobacillus spp. have been found to carry 
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antibiotic-resistance genes that are potentially transferrable (Campedelli et al., 2018). Moreover, many 
intestinal anaerobes are also antibiotic resistant (see below), possibly due to exposure of the host to the 
widespread use of antibiotics. Hence, there is a need to efficiently inactivate these in all health-promoting 
bacteria that reach the consumer.  
Optimization of existing probiotic bacteria can occur in various ways. A possible overlooked approach is the 
use of fermentation optimization. A recent example of this is the so-called upgrading of the fermentation of 
Propionibacterium freudenreichii, a less-often used probiotic strain and a natural producer of vitamin B12 
(Kajander et al., 2008; Piwowarek et al., 2018). This was realized in such a way that the cells of P. 
freudenreichii strain W200 now have adequate quantities of this vitamin as to retain an EFSA validated 
health claim (Winclove Probiotics, NL). Other well-known approaches include selection by random 
mutagenesis, forced evolution, CRISPR-Cas-mediated genome editing or use of cryptic plasmid and food-
grade vectors (Derkx et al., 2014). These and others allow tailoring of the coding capacity of probiotic 
strains with respect to their intended applications. However, it has to be kept in mind that some 
technologies generate bacterial variants that may be considered in some countries as genetically modified 
organisms (GMOs). Since the application of such GMOs is highly restricted, non-GMO approaches have a 
wider range of applications in industry. In Lactobacillus rhamnosus strain GG, random mutagenesis was 
carried out to generate non-GMO variants devoid of mucus-binding pili as a result of either mutations 
within the pilus gene cluster or large chromosomal rearrangements (Rasinkangas et al., 2014). Following a 
similar approach, L. rhamnosus GG derivatives with a higher mucus adherence were also obtained 
(Rasinkangas, 2016). This exemplifies how the performance of a specific trait can be altered to generate a 
range of phenotypes for the same strain. Adhesion ability and tolerance to glucose-induced carbon 
catabolite repression in L. plantarum strains were improved using random mutagenesis (Seme et al., 2017; 
Zhao et al., 2017). Random mutagenesis is a rather unspecific approach, since secondary/unwanted 
mutations also occur with possible and deleterious impact on the phenotype. However, in combination 
with high throughput next-generation sequencing the undesired strains can be easily detected and 
removed from the selection process (Rasinkangas et al., 2014). A more direct approach is the use of GMO 
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approaches that have also been extensively used to improve the adaptation of strains to the gut 
environment. Thus, the tolerance to acid and high osmolarity in L. salivarius strain UCC118 was improved 
by expressing betL coding for betaine uptake system in Listeria monocytogenes (Sheehan et al., 2006). On 
the other hand, GMO approaches have also used for the display of antigens or antibodies as recently 
reviewed (Michon et al., 2016; Szatraj et al., 2017) and the production of recombinant proteins, i.e. human 
recombinant phenylalanine hydroxylase or interleukin IL-10 in L. plantarum (Cai et al., 2016; Ramirez et al., 
2017). The use of food-grade expression systems based on DNA homologous to the hosts or other food 
bacteria is typically preferred, since antibiotic resistance markers need to be avoided. Such an approach has 
been successful, as evidenced in L. lactis expressing the gene for elafin (a protease inhibitor) for the 
treatment of inflammatory bowel diseases (Motta et al., 2012) or secreting interleukin IL-10 for food allergy 
management (Robert and Steidler, 2014). An extensive range of LAB and bifidobacteria have been so far 
successfully bio-engineered, including among others, species like L. paracasei, L. lactis, L. salivarius or L. 
reuteri (Mathipa and Thantsha, 2017).  
Until now, GMO techniques have been mostly developed to modify the properties of probiotic bacteria as 
to better comprehend their mode of action in the gut. Only in few studies, bacterial strains were purposely 
engineered using conventional strategies for conducting human interventions (Robert and Steidler, 2014). 
Over the last few years, the CRISPR-Cas genome editing tool has revolutionized research in life sciences and 
is about to have a similar impact on the bio-engineering of probiotic strains. The CRISPR-Cas system was 
successfully implemented in lactobacilli and bifidobacteria, although it may be differently effective among 
strains of the same bacterial species (Leenay et al., 2018). The potential applications of the CRISPR-Cas 
mediated engineering system in probiotic bacteria highlight the promise for significant advances in the 
development of health-promoting bacteria with enhanced probiotic properties or specifically tailored for a 
given application (van Pijkeren and Barrangou, 2017). The regulatory status of the revolutionary CRISPR-Cas 
based genome-editing technology is, however, presently controversial and being subject to different 
regulatory regimes in various parts of the world (Mougiakos et al., 2016).  
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5. Microbiome-based next-generation therapeutic bacteria  
Most of the insight into the human microbiome has been based on 16S rRNA or metagenome analysis, only 
providing information on the gut microbiota at the genus or group level. However, when the bacterial 
signatures are very marked, associations with health parameters can be made and may identify potential 
next-generation species. Only when cultured representatives are available, causal relations can be 
established. Presently, type strains of over 1000 species have been described and deposited in accessible 
strain collections (Rajilić-Stojanović and de Vos, 2014). This illustrates the fact that there is some choice and 
in many cases, various strains from the same bacterial species are available allowing approaches as 
discussed for the screening of novel probiotic microbes (Figure 3). Following the selection of an appropriate 
strain, safety and causality studies are often performed in mouse models even while it is known that the 
mouse microbiota differs considerably from that in human (Hugenholtz and de Vos, 2018). However, these 
models have the additional advantage to provide insight in the safety of the candidate strains. This has 
been the case with several of the health-promoting anaerobes belonging to the major phyla in the human 
gut, including the Bacteroidetes, Firmicutes and Verrucomicrobia (Figure 1). While the mechanisms of 
action of these next-generation therapeutic bacteria are being studied in detail, several produce butyrate 
and the production of this short chain fatty acid is a characteristic that is not found among the canonical 
probiotic strains and may explain some of the health benefits (Schroeder and Backhed, 2016). Examples are 
discussed below with specific attention for their characteristics, safety aspects, and application potential. In 
addition, in some cases comparisons, are made with the approaches discussed for new probiotic strains. 
Bacteroidetes are true Gram-negative bacteria that have high abundance in the human intestinal tract of 
approximately 20-40 % (Arumugam et al., 2011). This phylum comprises various genera, the most notable 
being Bacteroides for which there are at least 25 species validly described, including some potentially 
pathogenic ones (Rajilić-Stojanović and de Vos, 2014). Some Bacteroides spp. have found to be, contain 
structures that are immunochemically identical to the alpha-Gal epitope or the Thomsen-Friedenreich (TFα) 
antigen, a tumor-specific carbohydrate antigen (Henderson et al., 2011). Interest in a potential new 
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therapeutic that could evoke an immune reaction focused on B. xylanisolvens, a strict anaerobe which 
degrades xylan and other sugars into acetate, propionate and succinate (Chassard et al., 2008). Likely based 
on the notion that non-viable B. xylanisolvens may still contain the desired structure and induce the desired 
immune response, an elaborate safety assessment was performed for pasteurized cells and it was 
concluded that heat-treated milk products fermented with the type strain B. xylanisolvens DSM 23964 
would be safe for use in humans under certain conditions (EFSA NDA Panel, 2015). A subsequent human 
trial confirmed that pasteurized B. xylanisolvens DSM 23964 is capable of inducing immunoglobulin M 
serum antibodies against the TFα antigen (Ulsemer et al., 2016). However, details on the application of B. 
xylanisolvens DSM 23964 in either the food or pharma space are missing. It is of interest to note though 
that the safety evaluation B. xylanisolvens DSM 23964 was performed in the knowledge that its genome 
contains a functional cepA gene coding for penicillin resistance – as this gene is widely spread in 
Bacteroides spp., apparently not located on a conjugative element, and the cells are pasteurized, it was 
concluded that this is not a risk factor (EFSA NDA Panel, 2015). Future studies will show what benefits the 
B. xylanisolvens pasteurized product will have, what mode of action could explain the results, and what 
markets it will address. 
One of the largest group of intestinal bacteria in both abundance and species richness is that of the 
Firmicutes (Qin et al., 2010). This phylum also contains the Lactobacillicaeae that include canonical 
probiotic strains but their abundance in the intestinal tract is very modest with 1% at most. Much more 
abundant are a wide range of anaerobes that among others belong to the class of Clostridia and include 
Clostridiaceae, Ruminococcaceae, Lachnospiraceae and Christensenellaceae. The Clostridia make up a 
significant part and were named after the Clostridium type species C. butyricum that was discovered over 
100 years ago (Rajilić-Stojanović and de Vos, 2014). C. butyricum is a spore-forming anaerobe capable of 
producing butyrate, butanol and 1,3-propanediol, while vigorously producing hydrogen. Interestingly, the 
non-toxigenic C. butyricum strain MIYAIRI 588 has been widely marketed in Asia and has it was shown to 
reduce symptoms in infants with antibiotic associated diarrhea (Seki et al., 2003). Moreover, this strain was 
also able to reduce growth of pathogenic Clostridium difficile in a rodent model (Oka et al., 2018). 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Interestingly, C. butyricum MIYAIRI 588 is not a gut commensal as it has been isolated from a Japanese soil 
sample. While its genome has not been reported yet, the strain carries a plasmid that has been 
characterized at the sequence level and was found to encode a butyricin-like bacteriocin with bactericidal 
properties (Nakanishi and Tanaka, 2010). This may at least partially explain the effectiveness of C. 
butyricum MIYAIRI 588 but so far no survival or colonization studies in human have been reported. The 
genome of a related strain of C. butyricum, strain DKU-01 isolated from infant feces, has been determined 
and found to encode the utilization of fructo-oligosaccharides but no functional studies of this strain have 
been performed yet. A recent review has addressed potential issues related to safety of C. butyricum 
strains as these are often found in infants with necrotizing enterocolitis (Cassir et al., 2016). Nevertheless, 
since C. butyricum MIYAIRI 588 has a long history of safe use, it is allowed on the EU market (Commission 
2014/907/EU). 
Bacteria belonging to the Ruminococacceae and Lachnospiraceae, previously known as Cluster IV and 
Cluster XIVa Clostridia, respectively, form the most abundant intestinal anaerobes and include some 
representatives that have been studied as next-generation health-promoting bacteria. Faecalibacterium 
prausnitzii belonging to the Ruminococacceae has received most attention since it is among the most 
prominent bacterial groups in the intestinal tract, varying from a few to fifteen percent of the total 
bacterial population (Lopez-Siles et al., 2017). Likely because of its abundance and relatively easy detection, 
there have been an impressive number of studies describing a reduced abundance of bacteria related to F. 
prausnitzii in patients with several human diseases, notably ulcerative colitis and Crohn's disease (Miquel et 
al., 2013). However, recent sequencing studies showed that there are at least three different F. prausnitzii 
phylogroups, likely representing different species (Benevides et al., 2017). This complexing factor illustrates 
the difficulties of the present state of the art of the intestinal microbiome research. Strain F. prausnitzii A2-
165 was studied first in an set of elegant experiments that have shown causality of its cells as well as 
culture supernatant that were capable of protecting mice in a colitis model (Sokol et al., 2008). Of interest 
has been the observation that a proteinaceous fraction of F. prausnitzii A2-165 was capable of partly 
reproducing this effect opening the way for more detailed molecular and mode of action studies (Quevrain 
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et al., 2016). In addition, the biofilm forming F. prausnitzii strain HTF-F has been used to show anti-
inflammatory effect in vitro (Rossi et al., 2016). Recently, a comprehensive set of comparative studies were 
described for a dozen F. prausnitzii isolates showing considerable differences in oxygen sensitivity, 
antibiotic resistances and immunomodulatory properties (Martin et al., 2017). This is in line with another 
study that showed variability in improving barrier function of various F. prausnitzii strains and noted that 
strains A2-165 and HTF-F did not affect this parameter (Maier et al., 2017). All these findings are 
reminiscent of probiotic bacteria that in most cases show strain–specific effects and illustrate the 
heterogeneity of the F. prausnitzii group. However, the detailed comparative studies are of great interest 
since they offer the possibility to select strains that are effective, do not carry antibiotic resistance genes, 
and can be grown on a large scale as to allow their production for human intervention, very much along the 
same lines as novel probiotic strains (Figure 3). In this context it is of interest to note that the oxygen-
sensitive F. prausnitzii strain A2-165 could be kept alive at ambient oxygen concentration when formulated 
with the antioxidants cysteine and riboflavin plus the cryoprotectant inulin (Khan et al., 2014). The safety of 
F. prausnitzii should be further addressed as it has been recently suggested (Brodmann et al., 2017). 
Following a comprehensive analysis of the microbiota of a large twin cohort, it was found that bacteria 
belonging to the Christensenellaceae were highly heritable and linked to a lean phenotype (Goodrich et al., 
2014). The first and so far only isolate of Christensenellaceae is Christensensella minuta DSM 22607, a small 
and non-spore forming anaerobe that is capable of producing butyrate from a few sugars. While it belongs 
to the Firmicutes, it stains like a Gram-negative bacterium, a feature also observed for F. prausnitzii. In a 
single experiment, this strain was grown and used to amend a fecal sample from an obese subject resulting 
in a reduced weight gain of the mice. This interesting finding sparkled interest in C. minuta although no 
repeat studies of the successful spiking have been yet described. Its 2.5 Mb- genome has been analyzed 
(Rosa et al., 2017; Yang et al., 2018) (Table 1). Detailed analysis revealed it to contain several resistance 
genes, including the tetW gene encoding tetracycline resistance. Whether C. minuta is a real Gram-negative 
bacterium needs to be addressed but it has been found produce an unusual lipopolysaccharide (LPS) that 
has limited agonist activity in ex vivo models as compared to the LPS of the well-known Gram-negative 
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Escherichia coli (Yang et al., 2018). A recent report described C. minuta to be present together with 
Desulfovibrio isolate in the blood of an appendicitis patient (Alonso et al., 2017). The presence of LPS, and 
the presence of potentially transferable resistance genes may indicate that a detailed toxicity analysis is 
needed before human trials of this interesting species could be considered.  
Causality has been addressed in the development of Eubacterium hallii as a next-generation therapeutic 
microbe by using fecal microbiota transplantation. Metabolic syndrome adults improved their insulin 
sensitivity significantly only after a duodenal infusion with fecal microbiota from a healthy donor but not 
with their own microbiota (Vrieze et al., 2012). Detailed analysis showed that the microbiota in the upper 
intestinal tract microbiota showed more differences than that in the colon. It was observed in duodenal 
biopsies that bacteria related to Eubacterium hallii were relatively increased in subjects receiving a healthy 
donor transplantation as compared to autologous controls (Vrieze et al., 2012). Eubacterium is a genus that 
is clearly not monophyletic and while some of its species belong in the Ruminococcaceae, the butyrate-
producing E. hallii has a different phylogenetic position and is grouped in the Lachnospiraceae (Rajilić-
Stojanović and de Vos, 2014). E. hallii is a metabolically highly versatile bacterium that is not only capable 
of producing butyrate from glucose and other sugars but also converts both D- and L- lactate to butyrate in 
presence of acetate (Duncan et al., 2004). Moreover, recently E. hallii has also been reported to produce 
propionate from 1,2-propanediol, an intermediate that can be generated from rhamnose and fucose 
(Engels et al., 2016). Following the human fecal microbiota transplant study, a trial with obese and diabetic 
mice was performed with E. hallii strain L2-7 that had been isolated from a healthy infant (Duncan et al., 
2004). This resulted in improvement of insulin sensitivity and adiposity in a dose-dependent way while 
active cells of E. hallii L2-7 were found to increase fecal butyrate concentrations, modify bile acid 
metabolism and reduced liver triglyceride levels (Udayappan et al., 2016). Moreover, expression studies 
showed that notably small intestinal rather than colonic genes were affected by live. This can be 
rationalized since the upper intestinal tract is much less densely populated than the colon and contains 
microbes that mainly produce lactate and acetate (Zoetendal et al., 2012). The conversion in the small 
intestinal of lactate and acetate into butyrate could be a mechanism by which E. hallii L2-7 could improve 
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metabolic health, in line with its potential action in the fecal transplantation trial. New insight based on 
genomic and physiological characteristics has led to adapt the phylogenetic position of E. hallii and this has 
now been classified into the genus Anaerobutyricum with two species, A. hallii including the type strain and 
A. soehngenii, including strain L2-7 (Shetty et al., 2018). Butyrate production from lactate and acetate is 
only mediated by a small group of intestinal bacteria, including these Anaerobutyricum spp. as well as the 
related Anaerostipes spp. and this has recently been studied in detail revealing a new and characteristic 
pathway involved in this conversion (Shetty, 2019). These specialized butyrate producers may have all 
potential for the development as next-generation therapeutic bacteria, notably for the treatment of 
subjects with metabolic syndrome to prevent the development of type 2 diabetes. 
While most industrial probiotic strains have been derived from human, some also have an animal origin. 
This is notably the case for B. animalis subsp. lactis BB-12 that is used worldwide in food products. A similar 
situation is the case for Butyricicoccus pullicaecorum that was described a decade ago as a new species 
when several strains were isolated from the cecum of oligo fructose-fed chicken and found to produce 
butyrate from variety of sugars (Eeckhaut et al., 2008). Initially described as belonging to the 
Ruminococcaceae, B. pullicaecorum also has been grouped in the Unclassified Clostridia, also belonging to 
the Firmicutes (Rajilić-Stojanović and de Vos, 2014). Following the observation that the average number of 
Butyricicoccus spp. in stools from patients with inflammatory bowel disease was significantly than that of 
healthy subjects, the B. pullicaecorum type strain 25-3T was selected for further analysis. A remarkable 
protective effect was observed upon oral administration of this strain in a colitis mouse model (Eeckhaut et 
al., 2013). Favorable rat safety trials have been reported of B. pullicaecorum strain 25-3T and its partial 
genome sequence was determined (Steppe et al., 2014). This showed the presence of a complete tetW 
gene but unexpectedly the tetracycline resistance of the type strain was low although other antibiotic 
resistances were reported (Steppe et al 2014). To further its potential application, a safety trial in healthy 
adults was recently reported that showed encapsulated B. pullicaecorum strain 25-3T to be safe and well 
tolerated in human (Boesmans et al., 2018). While there was no impact on the overall microbial community 
composition, unexpectedly no accumulation of the treatment genus over the intervention study was 
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observed. However, this may be due to the relatively high baseline level of the genus Butyricicoccus. As this 
is the case with many next-generation therapeutic bacteria, there are no media that can be used to 
selectively enumerate the administered strain. However, deep metagenomic sequencing in combination 
with advanced computational methods can allow strain level analysis as recently reported (Li et al 2016). 
Alternatively, the strain may have lysed during transit but this is unlikely since its encapsulation was tested 
thoroughly (Eeckhaut et al., 2014). It is of great interest to follow the further development of B. 
pullicaecorum strain 25-3T as a candidate for next-generation therapeutic bacteria that could have clinical 
benefits in inflammatory bowel disease.  
Recent years have seen a rapidly increasing attention in Akkermansia muciniphila, the sole representative 
of the Verrucomicrobia in the human intestinal tract that was discovered in a search for mucus-degrading 
commensals with the idea that these would interact beneficially with the host (Derrien et al., 2004). Some 
of this attention can be explained as A. muciniphila can be detected easily because of its deeply rooted 
phylogenetic position. Hence it stands out in many microbiota profiling studies and the presence of A. 
muciniphila has been associated with health in dozens of studies (Derrien et al., 2017). Germ-free mice 
mono-associated with A. muciniphila showed marked metabolic and immune signaling in the colon while in 
the same analysis L. plantarum was signaling mostly in the upper intestinal tract (Derrien et al., 2011). 
Subsequent studies demonstrated that living A. muciniphila cells were capable of protecting mice from 
diet-induced obesity and improved barrier function (Everard et al., 2013). Many studies confirmed this and 
the improvement of colonic barrier function by A. muciniphila has been reproduced in many different 
laboratories around the world (Cani and de Vos, 2017). This supported the original hypothesis of host 
interaction and is in line with the abundance of A. muciniphila in the colon where it can reach in healthy 
subjects levels of around 2-5 %, while phylogenetic and genomic analysis showed that present isolates all 
belong to the same species (Belzer and de Vos, 2012; Geerlings et al., 2018). The mode of action has been 
studied using molecular approaches and identified a specific outer membrane protein Amuc_1100 that was 
signals to the TLR2-receptor and is capable of reproducing the effect (Ottman et al., 2016; Plovier et al., 
2017). The 30 kDa Amuc_1100 protein is relatively heat stable explaining why also pasteurized cells of A. 
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muciniphila were capable of improving barrier function and protecting mice from diet induced obesity 
(Plovier et al., 2017). This opens avenues to produce stable and inactivated A. muciniphila cells that could 
be used as supplements or other formulations. A. muciniphila could be produced in animal-component free 
media (describe above) and thus produced cells were used in human trials to assess its safety making this 
unusual commensal one of the most promising candidate as a next-generation therapeutic (Plovier et al., 
2017). In addition, the Amuc_1100 protein could serve well as a vehicle to induce barrier function in a 
clinical settings and this is currently under investigation.  
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6. Concluding remarks 
Current probiotic-marketed products mainly consists of bacterial strains belonging the canonical 
lactobacilli-bifidobacteria group. These strains have been isolated and further selected for their natural 
probiotic traits and their compatibility with industrial processes and product formulation. Revolutionary 
bio-engineering tools, such as the CRISPR-Cas system, and the explosion of microbiomics are now 
challenging this established scheme and will contribute hand-in-hand to the rational design of bacterial 
strains with enhanced/tailored probiotic properties compared to their wild-type counterparts and the 
emergence of a whole new array of microbiota-derived species or strains that harbor traits absent in 
traditional probiotics. These major developments in the field of health-promoting bacteria hold great 
promise for the future development of functional products with better performance and tailored functional 
properties that are targeting very specific applications. Moreover, the microbiome-based next-generation 
therapeutic bacteria are developing rapidly, target a great variety of new health functions, and hence hold 
great potential for the food and pharma industry.  
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Table 
Table 1. List of common bacterial species whose members are harboring health-promoting properties. Their 
respective phylogenetic relatedness is shown in Figure 1. For each species is indicated the number of deposited closed 
genomes and assemblies as retrieved from in NCBI databases on the date of 27
th
 October 2018.  
 
Bacterial Species 
Closed 
Genome 
Genome 
Assemblies 
Genome 
Example Origin References 
Traditional probiotic 
bacteria       
 
Lactobacillus acidophilus 6 36 NCFM 
Human 
intestine 
(Altermann et al., 2005) 
 
Lactobacillus brevis 13 53 ATCC 367 Undefined (Makarova et al., 2006) 
 
Lactobacillus casei 6 24 BL23 Cheese (Maze et al., 2010) 
 
Lactobacillus helveticus 13 50 DPC 4571 Cheese (Callanan et al., 2008) 
 
Lactobacillus jensenii 1 18 SNUV360 Vagina (Lee et al., 2017) 
 
Lactobacillus paracasei 21 109 N1115 
Fermented 
milk 
(Wang et al., 2014) 
 
Lactobacillus plantarum 67 304 WCFS1 Human saliva (Siezen et al., 2012) 
 
Lactobacillus reuteri 12 118 DSM 20016 
Human 
intestine 
(Sun et al., 2015) 
 
Lactobacillus rhamnosus 16 151 GG 
Human 
intestine 
(Kankainen et al., 2009) 
 
Lactobacillus salivarius 
subsp. salivarius 
8 83 UCC118 
Human 
intestine 
(Claesson et al., 2006) 
 
Lactococcus lactis subsp. 
lactis 
37 150 IL1403 Cheese (Bolotin et al., 2001) 
 
Bifidobacterium animalis 
subsp. lactis 
20 50 BB-12 Infant feces (Garrigues et al., 2010) 
 
Bifidobacterium bifidum 9 58 BGN4 Infant feces (Yu et al., 2012) 
 
Bifidobacterium breve 38 93 UCC2003 Infant feces 
(O'Connell Motherway et 
al., 2011) 
 
Bifidobacterium longum 20 172 JDM301 Infant feces 
(Wei et al., 2010) 
 
 
 
 
Next-generation 
therapeutic bacteria 
Propionibacterium 
freudenreichii 
23 45 
CIRM-
BIA129 
Cheese (Falentin et al., 2016) 
 
Akkermansia muciniphila 2 56 
ATCC BAA-
835 
Human feces (van Passel et al., 2011) 
 
Bacteroides xylanisolvens 0 18 XB1A Human feces Direct submission 
 
Butyricicoccus 
pullicaecorum 
0 3 25-3(T) 
Chicken cecal 
content 
(Steppe et al., 2014) 
 Christensenella minuta 0 3 DSM22607 Human feces (Rosa et al., 2017) 
 
Clostridium butyricum 5 20 DKU-01 Infant feces (Mo et al., 2015) 
 
Eubacterium hallii 1 9 L2-7 Infant feces (Shetty et al., 2017) 
 
Faecalibacterium prausnitzii 4 40 A2-165 Human feces (Benevides et al., 2017) 
 
 
 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Figures 
Figure 1. Rooted phylogenetic tree of bacterial species that have been shown to display health-promoting properties. 
The tree was generated using the online analysis resource from PATRIC (Wattam et al., 2017) and rendered using 
Phylo.io (Robinson et al., 2016). The present tree aims at illustrating the growing phylogenetic diversification of 
bacterial species that are positively associated with human health rather than providing an overview of all bacterial 
taxa that are marketed as probiotics. For clarity, not all known and relevant bacterial species were included. Legend: 
blue, traditional probiotics; green, next-generation probiotics. 
 
Figure 2. Biotechnology of health-promoting bacteria: an overview. Novel insights into the gut microbiota and the 
parallel development of new technologies are opening new avenues for the use and enhancement of existing and 
novel probiotic species/strains. 
 
Figure 3. Workflow for the selection of health-promoting bacteria based on omic approaches and in silico predictive 
models. 
 
Figure 4. Bio-engineering health-promoting bacteria to increase probiotic potential and impact on gut health. Through 
the use of various genetic engineering or mutation-selection strategies, the coding capacity of probiotics can be 
altered to further improve colonization, stress resistance, stability, quorum-sensing, host interaction or to produce 
active compounds and nutrients, i.e. short chain fatty acids and vitamins. Such approaches would also allow the 
development of tailored probiotics specific to a given application, disease or health condition. 
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